S.Korea reaches deals to buy more COVID-19 vaccines for 23 million people

With a population of 52 million, South Korea had already secured enough doses for 56 million people from COVAX, Pfizer, Moderna, AstraZeneca and Johnson & Johnson, and is due to begin its first stage of vaccinations on Feb. 26. On Monday authorities said they would not use AstraZeneca's coronavirus vaccine on people aged 65 and older, reversing an earlier decision, and scaled back initial vaccination targets because of delayed shipments from global vaccine-sharing scheme COVAX.

Reuters | Updated: 16-02-2021 06:20 IST | Created: 16-02-2021 06:20 IST
S.Korea reaches deals to buy more COVID-19 vaccines for 23 million people

South Korea has arranged to buy coronavirus vaccines for 23 million more people, its prime minister said on Tuesday, a day after authorities said delays and efficacy concerns meant fewer people would be vaccinated in the first quarter of the year. The deals include Novavax vaccines for 20 million people and Pfizer products for 3 million, Prime Minister Chung Sye-kyun said in remarks at a meeting that were broadcast.

"The government has been working to bring in sufficient early supplies, but there is growing uncertainty over our vaccination plan for the first half due to production issues with global drugmakers and international competition to adopt more vaccines," he said. With a population of 52 million, South Korea had already secured enough doses for 56 million people from COVAX, Pfizer, Moderna, AstraZeneca and Johnson & Johnson, and is due to begin its first stage of vaccinations on Feb. 26.

On Monday authorities said they would not use AstraZeneca's coronavirus vaccine on people aged 65 and older, reversing an earlier decision, and scaled back initial vaccination targets because of delayed shipments from global vaccine-sharing scheme COVAX. The country slashed its first-quarter target for how many people would be vaccinated from 1.3 million to less than 760,000.

The director of the Korea Disease Control and Prevention Agency (KDCA), Jeong Eun-kyeong, said the first-quarter adjustments were not expected to affect the goal of achieving "herd immunity" by November, though some independent health experts have cast doubts on the feasibility of that timeline. The KDCA reported 457 additional coronavirus cases as of midnight on Monday, bringing South Korea's total to 84,325 with 1,534 deaths.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)


TRENDING

OPINION / BLOG / INTERVIEW

Why unequal access to coronavirus vaccines is a threat to us all

... ...

India’s love affair with fossil fuels: the path to sustainable development?

... ...

Videos

Latest News

China reports 16 new COVID-19 cases vs 9 a day earlier

China reported 16 new coronavirus cases in the mainland for Feb. 15, compared to nine a day earlier, the health commission said on Tuesday. All the cases were imported infections originating overseas, and there was no new death or new suspe...

NZ says Australia abdicated responsibilities over dual citizen arrested in Turkey

New Zealands Prime Minister Jacinda Ardern said on Tuesday that Australia had abdicated its responsibilities by unilaterally cancelling the citizenship of a woman who was arrested in Turkey with alleged links to the Islamic State.Turkish au...

Australia medical regulator approves AstraZeneca's COVID-19 vaccine

Australias medical regulator said on Tuesday it had granted provisional approval for the COVID-19 vaccine developed by AstraZeneca, making it the second vaccine to get regulatory approval in Australia.The regulator last month approved the P...

Novavax signs deal with SK Bioscience for 40 mln vaccine doses for S. Korea

U.S. drug developer Novavax Inc said on Monday it has signed a license agreement with South Korea manufacturer SK Bioscience to produce 40 million doses of its COVID-19 vaccine for South Korea.Concurrently, SK Bioscience has finalized an ad...

Give Feedback